Review summary
Teaching objective: Recognize early-onset rectal cancer in a fit woman of 41, below the screening age, whose rectal bleeding and change in bowel habit could be put down to hemorrhoids, and care for it on the NCCN rectal cancer guideline and the ASCO guidance on locally advanced rectal cancer: a digital rectal examination and prompt colonoscopy with biopsy; mismatch repair testing of every colorectal cancer; germline genetic testing because she is under 50; staging by pelvic MRI and CT, with CEA; a multidisciplinary tumor board; and, because the tumor is mismatch repair deficient, PD-1 blockade with dostarlimab and a watch-and-wait strategy after a clinical complete response, sparing her the abdominoperineal resection and permanent colostomy that a tumor this low would otherwise need. The episode also covers immune-related adverse events (hypothyroidism), iron deficiency anemia, sexual health and body image, return to elite sport, screening of first-degree relatives, the USPSTF screening age of 45, and survivorship care, set against her documented operation with a permanent colostomy in 1880 and her return to win a national championship afterwards.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| June 26, 1911 | Born in Port Arthur, Texas; the family moves to Beaumont in 1915. | CLM-0001, CLM-0002 |
| 1932 | Wins two gold medals and a silver medal in track and field at the Los Angeles Olympic Games. | CLM-0003 |
| December 23, 1938 | Marries George Zaharias. | CLM-0004 |
| 1950 | Voted Associated Press Woman Athlete of the Half-Century, a year after co-founding the LPGA; about this time she buys the Tampa Golf and Country Club and lives there. | CLM-0005 |
| End of 1952 | Extremely fatigued by the end of the golf season. | CLM-0006 |
| April 17, 1953 | Diagnosed with cancer in April 1953; operation including a colostomy in Beaumont. | CLM-0007, CLM-0008 |
| July 1954 | Wins the U.S. Women's Open by twelve strokes, 14 months after the operation. | CLM-0009 |
| 1955 | The cancer returns; she re-enters John Sealy Hospital in Galveston in June and sets up a cancer fund with her husband in September. | CLM-0010, CLM-0011 |
| September 27, 1956 | Dies of cancer at John Sealy Hospital in Galveston at 45. | CLM-0012 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Mildred Ella Didrikson was born in Port Arthur, Texas, on June 26, 1911, the sixth of seven children of the Norwegian immigrants Ole Nickolene and Hannah Marie (Olson) Didriksen; she later changed the spelling of her surname. In 1915 the family moved to Beaumont, Texas. | confirmed | Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports Michals D, ed. Mildred "Babe" Didrikson Zaharias supports HISTMED Master Roster v3 context |
| D | Her birth year is given variously: she wrote 1914 on her application for the 1932 Olympics, and some sources, including a historical marker at her grave, give 1913, 1914 or 1915; her gravestone and baptismal certificate support 1911. Explains why her age is given differently, including in her obituaries; 1911 is used. |
confirmed | Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) supports |
| D | At the 1932 Olympic Games in Los Angeles she won gold medals in the javelin and the 80-meter hurdles and a silver medal in the high jump, where her head-first technique was ruled a foul. Anchors the modern social history: an elite athlete all her adult life. |
confirmed | Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports Michals D, ed. Mildred "Babe" Didrikson Zaharias supports |
| D | She met the professional wrestler George Zaharias at the 1938 Los Angeles Open, and they married on December 23, 1938; he became her manager. History only; her husband is given no role in the modern episode. |
confirmed | Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports Michals D, ed. Mildred "Babe" Didrikson Zaharias supports |
| D | She took up golf in 1933, won 17 amateur tournaments in a row between 1943 and 1947, co-founded the Ladies Professional Golf Association in 1949, and was voted the Associated Press Woman Athlete of the Half-Century in 1950. About 1950 she and her husband bought the Tampa Golf and Country Club in Florida and moved into its converted clubhouse. Anchors the modern social history: a professional golfer who lives at the golf club she owns in Tampa. |
confirmed | Michals D, ed. Mildred "Babe" Didrikson Zaharias supports Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports The Life and Achievements of Babe Didrikson Zaharias supports |
| D | By the end of the 1952 golf season she was feeling extremely fatigued. The anchor for the modern presenting problem (fatigue, rectal bleeding and a change in bowel habit). One source only; no other symptom before the diagnosis was found in the sources read. |
probable | Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports |
| D | She was diagnosed with cancer in April 1953 and had an operation that included a colostomy on April 17, 1953, in Beaumont, Texas. She missed the 1953 U.S. Women's Open while she recovered. The documented diagnosis and operation to which the modern diagnosis is linked. The colostomy was permanent; the modern episode avoids one. |
confirmed | Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports The Life and Achievements of Babe Didrikson Zaharias supports Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports Michals D, ed. Mildred "Babe" Didrikson Zaharias supports 1954 U.S. Women's Open; 1953 U.S. Women's Open supports |
| R | The sources read call her cancer colon cancer and do not name the operation or give any pathology. That it was a low rectal cancer removed by abdominoperineal resection is a retrospective reading of the permanent colostomy, which was then the usual result of that operation; some popular accounts call it rectal cancer. Retrospective. The modern episode uses a low rectal adenocarcinoma, which fits a permanent colostomy in 1953; this is a teaching choice, not a resolution of the historical question. |
possible | The Life and Achievements of Babe Didrikson Zaharias context Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) context 1954 U.S. Women's Open; 1953 U.S. Women's Open context |
| D | She was back in tournament competition 14 weeks after the operation, received the Ben Hogan Comeback Player of the Year award for 1954, and in 1954 won five tournaments, including the U.S. Women's Open, played on July 1 to 3 at Salem Country Club in Peabody, Massachusetts, which she won by twelve strokes. Documented return to elite sport after the operation; the modern plan is built around her golf. |
confirmed | Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) supports Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports 1954 U.S. Women's Open; 1953 U.S. Women's Open supports |
| D | The cancer returned in 1955: back surgery that year found cancer near her sacrum, and in June 1955 she re-entered John Sealy Hospital at the University of Texas Medical Branch in Galveston, where treatment could not contain its spread. Documented recurrence after the episode; history only. |
probable | Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports 1954 U.S. Women's Open; 1953 U.S. Women's Open supports The Life and Achievements of Babe Didrikson Zaharias supports |
| D | She was one of the first public figures to speak openly about her cancer, and raised money and awareness for cancer education and research; in September 1955 she and her husband set up the Babe Didrikson Zaharias Fund, which financed a tumor clinic at the University of Texas Medical Branch. The American Cancer Society gave her a certificate of appreciation. Her documented openness about cancer anchors the modern plan's attention to screening of relatives and public education. |
confirmed | The Life and Achievements of Babe Didrikson Zaharias supports Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) supports Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports |
| D | She died of cancer at John Sealy Hospital in Galveston, Texas, on September 27, 1956, at 45, and was buried in Beaumont. One reference work gives September 26, and the contemporary New York Times report gave her age as 42. The documented death from cancer, to which the synthetic diagnosis is linked. History only, stated without detail. |
confirmed | Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) supports The Life and Achievements of Babe Didrikson Zaharias supports Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) supports Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this week | resolved | confirmed | active | CLM-0006 |
| S | Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tiredness | active | confirmed | active | CLM-0006 |
| S | Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactly | active | confirmed | both_with_link | CLM-0007, CLM-0012, CLM-0008 |
| S | Acute viral upper respiratory infection with cough and sore throat, a week before cycle 4 of dostarlimab; oxygen saturation and chest X-ray normal, so immune-related pneumonitis is unlikely; rapid influenza and COVID-19 tests negative; resolved | resolved | confirmed | active | CLM-0007, CLM-0012 |
| S | Immune-related primary hypothyroidism from dostarlimab, grade 2: tiredness and cold hands, TSH 12.6 mIU/L and free T4 0.6 ng/dL after four doses, following a mild TSH rise four weeks earlier; dostarlimab continued | active | confirmed | active | CLM-0007, CLM-0012 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1953-03-16 | Hemoglobin [Mass/volume] in Blood | 11 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1953-03-16 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 77 fL (low) Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 1953-03-16 | Leukocytes [#/volume] in Blood by Automated count | 6.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1953-03-16 | Platelets [#/volume] in Blood by Automated count | 412 10*3/uL (high) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1953-03-16 | Ferritin [Mass/volume] in Serum or Plasma | 9 ng/mL (low) Reference 15-150 ng/mL |
http://loinc.org · 2276-4 |
| S | 1953-03-16 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1953-03-16 | Potassium [Moles/volume] in Serum or Plasma | 4.1 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1953-03-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1953-03-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 98 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1953-03-16 | Glucose [Mass/volume] in Serum or Plasma | 88 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1953-03-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1953-03-16 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1953-03-16 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 72 U/L Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 1953-03-16 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1953-03-16 | Albumin [Mass/volume] in Serum or Plasma | 4.3 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1953-03-16 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 5.8 ng/mL (high) Reference Up to 3.0 ng/mL in non-smokers |
http://loinc.org · 2039-6 |
| S | 1953-03-16 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 1953-03-30 | Hemoglobin [Mass/volume] in Blood | 11.1 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1953-03-30 | Leukocytes [#/volume] in Blood by Automated count | 6.5 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1953-03-30 | Platelets [#/volume] in Blood by Automated count | 405 10*3/uL (high) Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1953-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1953-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 101 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1953-03-30 | Glucose [Mass/volume] in Serum or Plasma | 90 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1953-03-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 17 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1953-03-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1953-03-30 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 1953-03-30 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1953-03-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 1953-03-30 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | http://loinc.org · 70274-6 |
| S | 1953-04-27 | Hemoglobin [Mass/volume] in Blood | 12.1 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1953-04-27 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 80 fL Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 1953-04-27 | Leukocytes [#/volume] in Blood by Automated count | 6.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1953-04-27 | Platelets [#/volume] in Blood by Automated count | 352 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1953-04-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.74 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1953-04-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 104 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1953-04-27 | Glucose [Mass/volume] in Serum or Plasma | 92 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1953-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1953-04-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1953-04-27 | Thyrotropin [Units/volume] in Serum or Plasma | 2.2 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 1953-04-27 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1953-04-27 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 3.4 ng/mL (high) Reference Up to 3.0 ng/mL in non-smokers |
http://loinc.org · 2039-6 |
| S | 1953-04-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 1953-06-01 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1953-06-01 | Leukocytes [#/volume] in Blood by Automated count | 9.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1953-06-01 | Platelets [#/volume] in Blood by Automated count | 290 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1953-06-01 | Thyrotropin [Units/volume] in Serum or Plasma | 5.8 mIU/L (high) Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 1953-06-01 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1953-06-29 | Hemoglobin [Mass/volume] in Blood | 13 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1953-06-29 | Leukocytes [#/volume] in Blood by Automated count | 6 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1953-06-29 | Platelets [#/volume] in Blood by Automated count | 268 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1953-06-29 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1953-06-29 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1953-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.75 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1953-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 102 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1953-06-29 | Glucose [Mass/volume] in Serum or Plasma | 89 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1953-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1953-06-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1953-06-29 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 70 U/L Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 1953-06-29 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1953-06-29 | Albumin [Mass/volume] in Serum or Plasma | 4.4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1953-06-29 | Thyrotropin [Units/volume] in Serum or Plasma | 12.6 mIU/L (high) Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 1953-06-29 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.6 ng/dL (low) Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1953-06-29 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 2.1 ng/mL Reference Up to 3.0 ng/mL in non-smokers |
http://loinc.org · 2039-6 |
| S | 1953-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 1953-08-10 | Thyrotropin [Units/volume] in Serum or Plasma | 3.1 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 1953-08-10 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1953-08-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 1953-10-05 | Hemoglobin [Mass/volume] in Blood | 13.4 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 1953-10-05 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 86 fL Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 1953-10-05 | Leukocytes [#/volume] in Blood by Automated count | 6.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1953-10-05 | Platelets [#/volume] in Blood by Automated count | 255 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1953-10-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.77 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1953-10-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M | 99 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1953-10-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1953-10-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 1953-10-05 | Ferritin [Mass/volume] in Serum or Plasma | 41 ng/mL Reference 15-150 ng/mL |
http://loinc.org · 2276-4 |
| S | 1953-10-05 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 1953-10-05 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1953-10-05 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 1.6 ng/mL Reference Up to 3.0 ng/mL in non-smokers |
http://loinc.org · 2039-6 |
| S | 1953-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 1953-10-05 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | http://loinc.org · 70274-6 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1953-03-16 | Body height | 168 cm | 8302-2 | S |
| 1953-03-16 | Body weight | 62.8 kg | 29463-7 | S |
| 1953-03-16 | Body mass index (BMI) [Ratio] | 22.3 kg/m2 | 39156-5 | S |
| 1953-03-16 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 1953-03-16 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1953-03-16 | Heart rate | 86 /min | 8867-4 | S |
| 1953-03-16 | Respiratory rate | 14 /min | 9279-1 | S |
| 1953-03-16 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1953-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1953-03-30 | Body height | 168 cm | 8302-2 | S |
| 1953-03-30 | Body weight | 62.6 kg | 29463-7 | S |
| 1953-03-30 | Body mass index (BMI) [Ratio] | 22.2 kg/m2 | 39156-5 | S |
| 1953-03-30 | Systolic blood pressure | 116 mm[Hg] | 8480-6 | S |
| 1953-03-30 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 1953-03-30 | Heart rate | 80 /min | 8867-4 | S |
| 1953-03-30 | Respiratory rate | 14 /min | 9279-1 | S |
| 1953-03-30 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1953-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1953-04-27 | Body height | 168 cm | 8302-2 | S |
| 1953-04-27 | Body weight | 63.2 kg | 29463-7 | S |
| 1953-04-27 | Body mass index (BMI) [Ratio] | 22.4 kg/m2 | 39156-5 | S |
| 1953-04-27 | Systolic blood pressure | 110 mm[Hg] | 8480-6 | S |
| 1953-04-27 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1953-04-27 | Heart rate | 70 /min | 8867-4 | S |
| 1953-04-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 1953-04-27 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1953-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1953-06-29 | Body height | 168 cm | 8302-2 | S |
| 1953-06-29 | Body weight | 63.8 kg | 29463-7 | S |
| 1953-06-29 | Body mass index (BMI) [Ratio] | 22.6 kg/m2 | 39156-5 | S |
| 1953-06-29 | Systolic blood pressure | 114 mm[Hg] | 8480-6 | S |
| 1953-06-29 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 1953-06-29 | Heart rate | 60 /min | 8867-4 | S |
| 1953-06-29 | Respiratory rate | 14 /min | 9279-1 | S |
| 1953-06-29 | Body temperature | 36.4 Cel | 8310-5 | S |
| 1953-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1953-10-05 | Body height | 168 cm | 8302-2 | S |
| 1953-10-05 | Body weight | 63.4 kg | 29463-7 | S |
| 1953-10-05 | Body mass index (BMI) [Ratio] | 22.5 kg/m2 | 39156-5 | S |
| 1953-10-05 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 1953-10-05 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1953-10-05 | Heart rate | 64 /min | 8867-4 | S |
| 1953-10-05 | Respiratory rate | 14 /min | 9279-1 | S |
| 1953-10-05 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1953-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 1953-06-01 | Body height | 168 cm | 8302-2 | S |
| 1953-06-01 | Body weight | 63 kg | 29463-7 | S |
| 1953-06-01 | Body mass index (BMI) [Ratio] | 22.3 kg/m2 | 39156-5 | S |
| 1953-06-01 | Systolic blood pressure | 114 mm[Hg] | 8480-6 | S |
| 1953-06-01 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1953-06-01 | Heart rate | 88 /min | 8867-4 | S |
| 1953-06-01 | Respiratory rate | 16 /min | 9279-1 | S |
| 1953-06-01 | Body temperature | 37.9 Cel | 8310-5 | S |
| 1953-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1953-08-10 | Body height | 168 cm | 8302-2 | S |
| 1953-08-10 | Body weight | 63.6 kg | 29463-7 | S |
| 1953-08-10 | Body mass index (BMI) [Ratio] | 22.5 kg/m2 | 39156-5 | S |
| 1953-08-10 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 1953-08-10 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1953-08-10 | Heart rate | 62 /min | 8867-4 | S |
| 1953-08-10 | Respiratory rate | 14 /min | 9279-1 | S |
| 1953-08-10 | Body temperature | 36.5 Cel | 8310-5 | S |
| 1953-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Professional golfer who plays tournaments and exhibitions and practices most days; an Olympic track and field champion in her youth; has never had colorectal cancer screening, which was not yet due at her age
- S Married, with no children; lives at the golf club she owns in Tampa, Florida, and keeps close ties to her family in Beaumont, Texas. No relative or companion is named or given a role in her care
- S Never smoker; alcohol rarely; no drug use; eats a varied diet with red meat most days
- S Periods regular; a levonorgestrel intrauterine device for contraception, placed three years ago; not planning a pregnancy; sexually active, with pain during sex and bleeding afterwards in recent weeks
- S Fiercely competitive and direct; wants plain facts, and wants to know what any treatment would mean for her game and whether she would need a bag
Functional status
- S Fully active; plays 18 holes and practices daily, though tired by the back nine for some months (ECOG performance status 0)
Mental status
- S Alert, quick and humorous; worried underneath; PHQ-2 negative; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning
- S Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months)
- S Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from iron
Procedures and immunizations
Procedures
- S Colonoscopy to the cecum with biopsy, under sedation: an ulcerated, friable mass on the posterior and left lateral wall of the lower rectum, about half the circumference, from 4 to 9 cm from the anal verge, not obstructing; six biopsies; the rest of the colon normal; no polyps. Pathology: invasive adenocarcinoma, moderately differentiated; immunohistochemistry shows loss of MSH2 and MSH6 with MLH1 and PMS2 retained; microsatellite instability high by PCR
- S Rectal-protocol MRI of the pelvis (high-resolution T2 and diffusion-weighted): low rectal tumor, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, posterior and left lateral, extending 4 mm beyond the muscularis propria (cT3b); two mesorectal lymph nodes of 7 mm with irregular borders (cN1); mesorectal fascia clear by 6 mm; no extramural venous invasion; no lateral pelvic nodes; sphincter complex not involved
- S CT of the chest, abdomen and pelvis with contrast: no liver, lung or peritoneal metastases; no enlarged retroperitoneal nodes
- S Colorectal multidisciplinary tumor board (medical oncology, colorectal surgery, radiation oncology, radiology, pathology, genetics, wound-ostomy nursing, nurse navigator): mismatch repair-deficient low rectal adenocarcinoma, cT3bN1M0; surgery would most likely need an abdominoperineal resection with a permanent colostomy; recommends PD-1 blockade with dostarlimab for six months, restaging by MRI and endoscopy about every three months, and watch-and-wait if there is a clinical complete response, with chemoradiation and surgery kept in reserve
- S Chest X-ray, two views: clear lungs, no consolidation, ground-glass change or effusion
- S Advance care planning conversation, about 20 minutes
- S Genetic counseling before germline testing: three-generation pedigree as she knows it, consent, and an explanation of what a positive or negative result would mean for her and her blood relatives
- S Restaging rectal-protocol MRI of the pelvis after four doses: marked regression, with low-signal fibrosis replacing most of the tumor and a small focus of intermediate signal with slight restricted diffusion at the lower margin; mesorectal nodes now 3 mm and smooth; near-complete response
- S Restaging flexible sigmoidoscopy after four doses: a flat white scar where the tumor was, with a 5 mm shallow ulcer at its lower edge; no mass
- S Final restaging rectal-protocol MRI of the pelvis after nine doses: low-signal fibrosis only, no intermediate signal and no restricted diffusion; no suspicious lymph nodes; complete response on MRI
- S Final restaging CT of the chest, abdomen and pelvis with contrast: no metastases
- S Final restaging flexible sigmoidoscopy after nine doses: a flat white scar with fine surface vessels; no ulcer, nodularity or mass; complete endoscopic response
Immunizations
- S 1948-05-10: Tdap vaccine
- S 1953-08-10: Hepatitis B vaccine (adjuvanted, two-dose series), dose 1
- S 1953-09-21: Hepatitis B vaccine (adjuvanted, two-dose series), dose 2, given in the infusion center with the last dose of dostarlimab
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Colonoscopy within one week, staging within two weeks, and a tumor board plan before treatment | 1953-03-30 | completed | Colonoscopy in three days, MRI and CT within nine days, tumor board in eleven days, consultation at two weeks |
| Germline genetic testing with counseling, and an explanation of the mismatch repair deficiency, within four weeks of diagnosis | 1953-04-27 | completed | Germline panel negative; two somatic MSH2 variants in the tumor explain the deficiency |
| Clinical complete response after six months of dostarlimab, with the rectum and sphincter preserved | 1953-10-05 | completed | Clinical complete response on MRI, endoscopy and examination after nine doses; watch-and-wait begun |
| Hemoglobin of 12 g/dL or more and ferritin above 30 ng/mL | 1953-10-05 | completed | Hemoglobin 13.4 g/dL and ferritin 41 ng/mL |
| Back to tournament golf during treatment | 1953-06-29 | completed | Playing 18 holes and entered in a club competition by the fourth visit |
| TSH within the reference range on thyroid replacement | 1953-08-10 | completed | TSH 3.1 mIU/L six weeks after levothyroxine began |
| PHQ-9 below 10 throughout treatment | 1953-10-05 | completed | PHQ-9 between 2 and 6 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Medical oncology (gastrointestinal) consultation within two weeks, with colorectal surgery, to review the colonoscopy and any biopsy with her and plan staging and treatment if cancer is found | completed | GL-NCCN-RECT-2026, GL-ASCO-LARC-2024 |
| Urgent work-up of rectal bleeding with a change in bowel habit and a rectal mass in a woman under 50: colonoscopy with biopsy within days, with mismatch repair testing of any cancer; blood count, ferritin, chemistry and CEA; if cancer is confirmed, rectal-protocol MRI of the pelvis and CT of the chest, abdomen and pelvis; return at once for heavy bleeding, fainting or inability to pass stool | completed | GL-NCCN-RECT-2026, GL-USPSTF-CRC-2021 |
| Oral iron for iron deficiency anemia from blood loss: ferrous sulfate 325 mg on alternate days, a blood count about four weeks after starting, ferritin at about three months, and iron continued for three months after the hemoglobin is normal | completed | GL-CMID-2026 |
| Germline multigene panel after genetic counseling, because she is under 50 and the tumor is mismatch repair deficient; tumor sequencing for somatic MMR variants if the germline panel is negative; colonoscopy for her first-degree relatives every five years from age 40, or 10 years before the age of her diagnosis if earlier, with Lynch syndrome surveillance only if a germline variant is found | completed | GL-ASCO-GERM-2024, GL-NCCN-RECT-2026, GL-USMSTF-2017 |
| Dostarlimab 500 mg intravenously every three weeks for nine doses (six months), with pelvic MRI, flexible sigmoidoscopy and digital rectal examination about every three months; blood count, kidney and liver tests and glucose before each dose and TSH with free T4 every six weeks; teaching about immune-related adverse events with a 24-hour line; hepatitis B, hepatitis C and HIV screening and a pregnancy test first; contraception continued during treatment and for four months after | completed | GL-NCCN-RECT-2026, GL-ASCO-LARC-2024, GL-CERCEK-2022, GL-CERCEK-2025, GL-ASCO-IRAE-2021, GL-ASCO-HBV-2020 |
| If the response is incomplete: chemoradiation and total mesorectal excision, as reviewed with the colorectal surgeon, with stoma site marking and teaching by a wound-ostomy nurse before any operation; fertility and sexual function counseling before any pelvic radiation | completed | GL-NCCN-RECT-2026, GL-ASCO-LARC-2024, GL-ASCO-FERT-2018 |
| Levothyroxine for immune-related hypothyroidism, with TSH and free T4 six weeks after starting and every six weeks while on PD-1 blockade; dostarlimab continued | completed | GL-ASCO-IRAE-2021, GL-CMID-2026 |
| Watch-and-wait after a clinical complete response: digital rectal examination and flexible sigmoidoscopy every three to four months and pelvic MRI every six months for two years, CEA every three to six months, CT of the chest, abdomen and pelvis every six to twelve months, colonoscopy at one year, and a written survivorship care plan; surgery at once for any regrowth | completed | GL-NCCN-RECT-2026, GL-CMID-2026, GL-CERCEK-2025 |
| Distress and depression screening at each visit; plain explanations with written information; attention to sexual health and body image and to her golf, with an exercise plan she sets; she decides who is told and who receives each note | completed | GL-USPSTF-DEP-2023, GL-ASCO-EX-2022 |
Planned encounters
- 1953-03-16 — Three months of rectal bleeding, narrower stools and urgency, with tiredness, in a professional golfer of 41: examination, blood tests, and colonoscopy this week (ENC-001)
- 1953-03-30 — Diagnosis of mismatch repair-deficient low rectal cancer: staging, tumor board plan, medical oncology and colorectal surgery consultation, genetic counseling, and the start of PD-1 blockade (ENC-002)
- 1953-04-27 — Day 1 of cycle 2 of dostarlimab: early response, immune-related adverse event checks, germline and tumor genetic results, iron and anemia, and golf (ENC-003)
- 1953-06-01 — Same-day sick visit for cough and sore throat during immunotherapy (ENC-006, unscheduled)
- 1953-06-29 — Restaging after four doses: pelvic MRI and endoscopy, immune-related hypothyroidism, and the decision to continue PD-1 blockade (ENC-004)
- 1953-08-10 — Periodic adult preventive visit during immunotherapy (ENC-007)
- 1953-10-05 — After nine doses: final restaging, clinical complete response, and the watch-and-wait surveillance plan (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Preventive Visit
- Progress note 07 — Focused Visit (Care-plan review)
- Medical Oncology (gastrointestinal) referral
- Medical Oncology (gastrointestinal) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Preventive Visit (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Medical Oncology (gastrointestinal) referral (XML)
- Medical Oncology (gastrointestinal) consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Cayleff SE. Zaharias, Mildred Ella Didrikson [Babe] (Handbook of Texas Online) | Texas State Historical Association | other |
| SRC-0002 | Michals D, ed. Mildred "Babe" Didrikson Zaharias | National Women's History Museum | other |
| SRC-0003 | Zaharias, Babe Didrikson (1911-1956) (Women in World History: A Biographical Encyclopedia) | Encyclopedia.com (Gale) | other |
| SRC-0004 | Winters K. Zaharias, Babe Didrikson (Notable Sports Figures) | Encyclopedia.com (Gale) | other |
| SRC-0005 | The Life and Achievements of Babe Didrikson Zaharias | Babe Didrikson Zaharias Foundation | other |
| SRC-0006 | 1954 U.S. Women's Open; 1953 U.S. Women's Open | Wikipedia | other |
| SRC-0007 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the MRI staging of a low rectal tumor, the choice of dostarlimab alone for mismatch repair-deficient locally advanced disease, the restaging schedule and the definition of clinical complete response, the reading of loss of MSH2 and MSH6 with a negative germline panel and two somatic MSH2 variants, the management of immune-related hypothyroidism without holding treatment, and the watch-and-wait surveillance intervals. |
| provenance review | not_started | She died in 1956; the recent-death rule does not apply. Claims rest on the Handbook of Texas (by her biographer Susan Cayleff), the National Women's History Museum, two Gale reference entries, the Babe Didrikson Zaharias Foundation and Wikipedia. The site of her cancer and the operation are recorded as R because the sources call it colon cancer and name no operation; everything clinical is synthetic. |
| safe messaging review | not_started | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative, companion or historical physician is given a role in the modern episode; her husband appears only in the documented history, and her close companion Betty Dodd is not used. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.